GAD1 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q99259 |
---|---|
Clone Names | 80513156 |
Gene ID | 2571 |
---|---|
Other Names | Glutamate decarboxylase 1, 67 kDa glutamic acid decarboxylase, GAD-67, Glutamate decarboxylase 67 kDa isoform, GAD1, GAD, GAD67 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | GAD1 (HGNC:4092) |
---|---|
Synonyms | GAD, GAD67 |
Function | Catalyzes the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) with pyridoxal 5'-phosphate as cofactor. |
Tissue Location | [Isoform 1]: Expressed in brain. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes one of several forms of glutamic aciddecarboxylase, identified as a major autoantigen ininsulin-dependent diabetes. The enzyme encoded is responsible forcatalyzing the production of gamma-aminobutyric acid fromL-glutamic acid. A pathogenic role for this enzyme has beenidentified in the human pancreas since it has been identified as anautoantigen and an autoreactive T cell target in insulin-dependentdiabetes. This gene may also play a role in the stiff man syndrome.Deficiency in this enzyme has been shown to lead to pyridoxinedependency with seizures. Alternative splicing of this gene resultsin two products, the predominant 67-kD form and a less-frequent25-kD form.
References
Lanoue, A.C., et al. Exp. Neurol. 226(1):207-217(2010)Jia, P., et al. Schizophr. Res. 122 (1-3), 38-42 (2010) :Terranova, C., et al. Alcohol 44(5):407-413(2010)Ruano, G., et al. Pharmacogenomics 11(7):959-971(2010)Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.